Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon retreatment in primary IgA nephropathy (NEF-301 completers)
CTR20220596Phase 3Completed
- Sponsor
- Everest Medicines
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of nefecon in IgA nephropathy (IgAN), sponsored by Everest Medicines. Started Mar 2022; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20220596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220596.